Clinical Trial Update: Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Cidecin (daptomycin) to Rocephin (ceftriaxone) for moderate to severe community-acquired bacterial pneumonia completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia Bacterial

Drugs mentioned

• Cidecin (daptomycin)
• Rocephin (Ceftriaxone)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Pneumonia, Bacterial | Phase 3 | Status: COMPLETED